Belite Bio Reports First-Quarter 2023 Operational

In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease (“STGD1”) trial (“LBS-008-CT02”), we continued to observe that oral Tinlarebant is...

Related Keywords

France ,Hong Kong ,Netherlands ,Germany ,Phoenix ,Arizona ,United States ,Belgium ,United Kingdom ,China ,Switzerland ,Australia ,Taiwan ,Tom Lin ,Belite Bio ,Tim Mccarthy ,Hendrik Scholl ,Michel Michaelides ,Jennifer Wu ,Nathanl Mata ,Institute Of Ophthalmology ,University Of Basel ,Department Of Ophthalmology ,Drug Administration ,Association For Research ,Exchange Commission ,Belite Bio Inc ,Facebook ,Geographic Atrophy ,Webcast Monday ,Chief Scientific Officer ,Upcoming Milestones ,Age Related Macular Degeneration ,Fast Track ,Rare Pediatric Disease ,Prospective Cohort Study ,Professor Hendrik Scholl ,Professor Michel Michaelides ,Cash Equivalents ,Investor Relations Contact ,Nasdaq Blte ,Nc ,